People

Liam Dahlberg is Associate at Eir Partners. Supports healthcare investment execution following Siris Capital and UBS financial sponsors and leveraged-finance experience. University of Georgia business graduate.

DJ McFarland is Associate at Eir Partners. Supports investment execution and portfolio initiatives following William Blair healthcare technology M&A experience. Indiana University Kelley finance graduate.

Arvind Iyengar is Senior Associate at Eir Partners. Healthcare technology investment professional with earlier Vector Capital, Corsair Capital and Lazard technology M&A experience. University of Chicago economics graduate.

Alex Antwan is Senior Associate at Eir Partners. Sources and executes healthcare technology investments and supports growth and M&A. Joined Eir in 2021; earlier Ziegler and Truist advisory experience and Miami University finance education.

Brandon Faresich is Vice President at Eir Partners. Investment professional with earlier Rubicon Founders, Court Square Capital and Bank of America Merrill Lynch experience. Holds a Wharton MBA and Notre Dame finance degree.

Jacob Brackmann is Vice President at Eir Partners. Healthcare investment professional with earlier Greater Sum Ventures and Founders Advisors experience; University of Alabama finance and accounting graduate education.

Thomas B. Raterman, also known as Tom Raterman, formerly served as Runway Growth Finance’s Chief Financial Officer, Chief Operating Officer, Treasurer and Secretary. He retired from the BDC officer roles effective June 30, 2026 and became Vice Chairman of the external adviser, Runway Growth Capital. His historical company officer role is retained separately from that current adviser function.

Robert Warshauer joined Runway Growth Finance’s board in 2025 as an independent director. He formerly led BLST Holdings and worked in investment banking and restructuring at Imperial Capital, Kroll Zolfo Cooper and Ernst & Young. He holds a business degree from Bucknell and an MBA from NYU. Other current BDC biographies qualify his BLST CEO position as former.

Yegor Elkin is Director at Eir Partners. Sources and executes healthcare investments and supports portfolio growth. Prior Madison Dearborn, MSD Partners and Deutsche Bank experience; Notre Dame finance degree. Current Director title supersedes older manager-site Vice President biography.

Julie Persily has served on Runway Growth Finance’s board since 2017 and is an independent director. She formerly co-led leveraged finance at Citigroup and Nomura and worked at Bankers Trust. She also serves on Investcorp Credit Management BDC’s board. She holds a BA in economics and psychology and an MBA from Columbia. Runway’s current chairman is Ted Goldthorpe; an older paragraph calling her chairman is stale.

Kevin McClellan is Vice President, Business Development at Eir Partners. Leads firm-wide business development and sourcing, with prior Waud Capital Partners, LaSalle Network and Auctus Capital Partners experience. University of Arizona business graduate.

Gary Kovacs has served as an independent director of Runway Growth Finance since 2016. He formerly led Accela, AVG Technologies and Mozilla and held technology leadership roles at SAP/Sybase, Adobe/Macromedia and IBM. He retired from Accela in January 2024; older Runway biographies describe that former CEO position as current. He holds commerce and MBA degrees from the University of Calgary.

Catherine Frey is an independent Runway Growth Finance director who joined its board in 2025. She co-founded F2P Ventures and previously worked at MatlinPatterson, Bear Stearns and Morgan Stanley. In September 2026 the WTA appointed her a player representative on its board and confirmed her Runway board role.

John Woody is Operating Partner at Eir Partners. Healthcare technology entrepreneur and operating partner who partnered with Brett Carlson during Eir’s first year. Previously led TransUnion healthcare initiatives and worked on Financial Healthcare Systems. Holds Duke biomedical and mechanical engineering education.

Alex Duka, also known as Alexander Duka, joined Runway Growth Finance’s board in 2025 as an independent director. He formerly worked for Citigroup for two decades and retired from its Financial Institutions banking group in 2017. He later led corporate development at Acceleration Bay. He holds undergraduate and MBA degrees from Rutgers.

Tim Fairbanks is Operating Partner & Head of Operations at Eir Partners. Former finance and operating executive at NationsHealth, Convey Health Solutions and Gainwell Technologies. Florida Atlantic University finance graduate with public-offering and acquisition integration experience.

Jennifer Kwon Chou joined Runway Growth Finance’s board in 2025 as an independent director. She is a co-founder, President and Partner of Torch Key Asset Management and a senior adviser to The Gores Group. She formerly led strategy at Gores and worked at Sterling Partners and Lehman Brothers. She studied at the University of Pennsylvania and Kellogg.

Ted Goldthorpe chairs Runway Growth Finance’s board, which he joined in 2025. He co-founded BC Partners Credit in 2017 and leads that business. He previously held leadership roles at Apollo Investment Corporation and Apollo Investment Management and worked at Goldman Sachs. He holds a commerce degree from Queen’s University.

Todd Leri is Operating Partner at Eir Partners. Former CareBridge chief growth officer and early employee; earlier founding-team commercial experience at Remedy Partners. University of Pennsylvania graduate.

Avisha Khubani is Chief Credit Officer of Runway Growth Capital and appears in the BDC’s public management directory in that adviser capacity. She joined Runway in 2018 and previously worked in valuation at Duff & Phelps. She is a CFA charterholder, holds an MBA from NYU Stern and an undergraduate degree from Montclair State.

Alan Huffman is Operating Partner at Eir Partners. Healthcare technology leader with former CareBridge, Aspire Health and Main Street Health technology leadership, including EHR, analytics and AI operational tools. Holds a Washington University in St. Louis computer-science master’s degree.

Colleen Corwell is Runway Growth Finance’s Chief Compliance Officer and an outsourced compliance executive. She is a Managing Director and head of US Financial Services Compliance and Regulation at Kroll, with experience serving investment advisers, investment companies and broker-dealers. She holds a BA from William and Mary and an MBA from Touro University.

Carmela Thomson became Chief Financial Officer, Treasurer and Secretary of Runway Growth Finance effective June 30, 2026. She joined the adviser in 2021 and previously worked as a senior audit manager at KPMG. She is a CPA and holds a degree in accounting and economics from Loyola University Chicago.

Jeff Martin is Operating Partner at Eir Partners. Healthcare and financial-services finance executive with prior Equian CFO experience and a Purdue degree. The current roster does not retain the older Chief Compliance Officer title; no current external employer appointment inferred.

Brett S. Carlson is Founder & Chief Executive Officer at Eir Partners. Founded Eir Partners in 2015 after healthcare investing and operating experience at Great Point Partners and iVantage Health Analytics. Founding investor and operator of Cloudmed; University of Pennsylvania graduate.

Michael Rovner, also called Mike, became Co-Chief Executive Officer of Runway Growth Finance in August 2026. He joined BC Partners through its 2023 acquisition of Ovation Partners, which he co-founded and led. He previously worked at Vida Capital and Austin Ventures and studied English at UCLA. His Co-CIO position belongs to the external adviser Runway Growth Capital.

Arizona State University professor and NewSpace director; chairs the consortium science council advising Lunar Dawn lunar terrain vehicle science, not an employee or corporate board director.

Retired U.S. Space Force lieutenant general and former U.S. Space Command deputy commander, appointed to the Lunar Outpost board in 2026.

Lunar Outpost co-founder directing company commercialization strategy and key flight programs; MIT aeronautics and astronautics doctorate and MOXIE science-team experience. CSO retained as published rather than assuming Chief Scientific Officer.

Theodore (Ted) Lundberg is Peloton Equity founding and managing partner; current own biography lists American Aerogel (doing business as AeroSafe Global) among his boards.

Peloton Equity partner; current primary biography explicitly lists the AeroSafe board.

Healthcare executive and NewSpring advisory partner; NewSpring current biography explicitly lists AeroSafe under Current Boards.

Maybell Quantum co-founder, identified in the company’s European headquarters announcement. The same September 2023 release describes him as COO; no newer own-source confirmation of that executive title was found, so only the enduring co-founder affiliation is entered.

Principal research engineer at Maybell Quantum, named in its March 2026 announcement discussing cryogenic cycles, distributed cooling, thermal transport and independent cooling nodes.

Co-founder and chief technology officer of Maybell Quantum, named in its March 2026 ColdCloud announcement discussing the foundational cryogenic innovations behind its cooling systems.

CEO of Maybell Quantum, leading commercialization and manufacturing expansion for its cryogenic and RF infrastructure. Named in the company’s September 2025 financing announcement and June 2026 QuantWare partnership announcement.

Published media and PR collaborations contact for Biorce. This establishes the named company affiliation and contact role, without asserting whether the engagement is employment or external consultancy.

Senior director of clinical solutions for Europe at Biorce, identified with an explicit company affiliation in its published October 2026 event programme.

Co-founder and chief scientific officer of Biorce, named by the company on its October 2026 event programme and demonstrating its Aika clinical development platform.

Founder and CEO of Biorce. His background in life sciences and experience trying to obtain a clinical trial for his father shaped the company’s focus on reducing delays in clinical development.

Technology entrepreneur with two prior exits and experience leading a fashion technology platform.

Has leadership experience in financial technology companies and leads Nūl’s commercial and product strategy.

Develops partnerships for commercial rooftop solar, drawing on solar sales and small business experience.

Leads engineering, design and project delivery, with prior manufacturing and process engineering experience at Fiat Chrysler.

Entrepreneur and engineer with previous strategy and growth leadership at Redbubble and experience building The Wine Collective.

Leads HiFeed’s cattle nutrition and emissions reduction business; also publicly listed under the shorter name Ihsan Akhirulsyah.

Founded Elevate Foods and served as its chief executive at the March 2024 pre-seed announcement.

Learn Capital adviser and co-founder and managing partner of Noetic, investing in mental health, CNS therapeutics, biotech, medical technology and wellness. Previously a managing director at Carlyle; co-founder of Grey House Partners and a Columbia economics and political science graduate.

Education economist Eric Hanushek, published as Rick Hanushek in Learn Capital’s adviser directory and identified by his full name in the same firm’s biography. Paul and Jean Hanna Senior Fellow at Stanford’s Hoover Institution and 2021 Yidan Prize recipient, researching education quality, teacher effectiveness and economic growth.

Learn Capital partner investing across seed, early-stage and growth-stage digital education companies. Previously led Teach For America’s Entrepreneurship & Innovation Initiative and worked at Amazon, the Chicago Public Education Fund and the Charter School Growth Fund; studied economics at Berkeley and earned an MIT Sloan MBA.

Chief financial officer and chief compliance officer at Learn Capital, overseeing fund accounting, operations and compliance. Previously a senior manager at Standish Management, with earlier roles at Goldman Sachs, PwC, Cambridge Place Investment Management and Everest Capital; holds an ACA qualification.

Executive assistant and workplace manager at Learn Capital, supporting its founder and managing partner and coordinating office services and resources. Previously worked in executive support, people operations and workplace management at Edmodo.

Managing partner of LearnStart, Learn Capital’s independently managed pre-seed and seed investing arm, as published on Learn Capital’s team directory. Previously built education businesses within Disney and Kaplan, founded education startups, and ran startup accelerators; studied at Harvard Business School and Duke.

Learn Capital partner with earlier experience in macro and commodities derivatives at Infinium Capital Management, macro futures and technical analysis at Yellowstone Capital Management and Raven Traders, and sales operations at Oscar Health Insurance and Kindred.

Learn Capital partner investing in education, workforce development and AI-enabled learning platforms. Leads the firm’s impact management practice and previously served as chief impact officer at Gary Community Ventures.

Founder and managing partner of Learn Capital who oversees its investing practice. Previously managed a Founders Fund affiliate and co-founded SmartDrive, Tachyon and Nextivity; has helped lead investments in Coursera, Udemy, General Assembly and Ascent.

Founder and managing partner of Learn Capital, investing in seed, early-stage and emerging-growth companies that transform learning and human capabilities. His published biography identifies early investments in Coursera, Udemy, Nerdy, General Assembly and Photomath, and board work with education and AI companies.

David Logue was Aktana’s publicly identified Chief Commercial Officer in2024. Aktana’s own event announcement identifies his work on healthcare-provider engagement, AI and mobile intelligence. This is a historical public appointment; continued employment after the January2026 asset acquisition has not been verified.

Jeremy Flax was publicly identified by Aktana in2025 as Vice President of Product Strategy, participating in its discussion of agentic AI for life sciences at NEXT Pharma Summit. Current independent Aktana employment after the January2026 asset acquisition is unverified.

Ramon Garcia joined Aktana as Vice President of Global Customer Success in2024, responsible for helping life sciences customers achieve strategic objectives and adopt new technology. Aktana’s own announcement describes his experience leading large-scale transformation programs. This historical role is not treated as a current PharmaForceIQ appointment.

Mark Desrosiers was appointed Aktana Chief Revenue Officer in2023 to lead its global sales organization and customer growth. Aktana’s own announcement describes more than two decades of technology leadership at Salesforce and Oracle. Current independent Aktana appointment following the January2026 asset acquisition has not been verified.

Emanuele Triggiano, also known as Manny Triggiano, joined Aktana’s executive team in2020 as Senior Vice President of Professional Services. He previously served as COO at Theorem and spent nearly20years in leadership roles at IMS Health. His Aktana responsibilities covered customer satisfaction, delivery operations and employee engagement. This is a documented historical appointment; current post-acquisition employment is unverified.

Dmitri Daveynis was Aktana’s Chief Technology Officer and Senior Vice President of Engineering, appointed in2020 to lead technology strategy, product development and cloud operations. His earlier leadership included Verint, Capsilon, Quantros, HP and Kodak. Flywheel’s current official leadership page identifies him as its CTO and explicitly describes his Aktana appointment as former; he is not represented as a current Aktana employee.

Kris Hinckley was Aktana’s publicly listed Vice President of People. She developed its people strategy and employee support frameworks, following roles in talent acquisition at SoFi and customer-service operations at Peet’s Coffee & Tea and UPS. Her background includes business administration and marketing at Eastern Montana College/Montana State University. Current independent Aktana appointment after the asset acquisition has not been verified.

Pini Ben-Or was Aktana’s publicly listed Chief Science Officer, overseeing AI and analytics innovation. He previously led analytics at NICE Actimize, developing machine-learning approaches to financial crime detection. His background spans optimization, decision theory, business intelligence and machine learning; he studied physics, mathematics and philosophy at Hebrew University and philosophy at Columbia. Current independent Aktana employment after the January2026 asset acquisition has not been verified.

David Ehrlich was a historical Chief Executive Officer and President of Aktana, an AI decision-support company for life sciences teams. The company’s 2016 financing release identifies him as CEO, and its 2020 SEC filings identify him as President, executive officer and director. John Vitalie became CEO effectiveJune20,2023. Aktana assets were acquired by PharmaForceIQ in January2026.

John Vitalie led Aktana as Chief Executive Officer from June20,2023. He previously led AI, SaaS, CRM and customer-experience businesses at Salesforce, Siebel and Oracle, and was CEO of Aizon. Aktana’s assets were acquired by PharmaForceIQ in January2026; continued independent Aktana CEO status has not been verified.

Nkiru Enendu leads customer engagement at PharmaForceIQ. Nkiru is a senior pharmaceutical marketing leader with over 8 years of experience driving omnichannel, patient-centric marketing across therapeutic areas including oncology, rare disease, and cardiorenal therapy.

Onika Davey leads human resources at PharmaForceIQ. Onika is strategic, internationally experienced HR leader with more than 15 years of global expertise spanning industries such as fashion and biotechnology. She brings a strong track record of optimizing HR operations.

Aditya Vagadia leads data analysis at PharmaForceIQ. Aditya leads PharmaForceIQ’s data analysis team, transforming complex healthcare datasets into strategic insights that drive commercial, medical, and market access decisions.

Kevin O'Connell leads business solutions at PharmaForceIQ. Kevin has two decades of experience helping biopharma leaders solve pressing commercial challenges to drive impact for patients and brands alike, including at Amplity Health, Delta Point, and Endo Pharmaceuticals.

Saraiyah Hatter leads customer engagement at PharmaForceIQ. Saraiyah is driven by a deep passion for marketing and strategy. From biopharma strategy consulting to leading omnichannel marketing campaigns, she thrives at the intersection of innovation and meaningful change.

Mike Bishop leads finance at PharmaForceIQ. Michael brings more than 15 years of experience leading accounting and finance teams. He spent more than 10 years with PwC in their audit practice, supporting small startups to multi-national Fortune 100 companies.

Sarah DeCristofaro leads marketing at PharmaForceIQ. Sarah leads marketing activities for PFIQ, applying her industry expertise from life science-focused roles at Phreesia, MedThink (a Fingerpaint Group company), and other organizations.

Mateo Polančec leads engineering at PharmaForceIQ. With AI and IT expertise in digital marketing and sales platforms, autonomous robotics, and more, Mateo has bridged advanced AI research with real-world engineering for eBay, Netflix, Volvo, and other global brands.

Derek Choy leads product at PharmaForceIQ. Derek is a product‑driven technology leader and entrepreneur with deep experience in building and scaling AI‑powered solutions, fostering innovation, and delivering customer‑centric products. Previously a cofounder and Chief Product Officer of Aktana, whose assets PharmaForceIQ acquired in January2026.

Stephen Onikoro leads operations at PharmaForceIQ. Stephen oversees operational functions and client relationships. He is a commercialization strategy expert, with more than 15 years of experience at BeiGene, PwC, Deloitte, and IQVIA.

Hemal Somaiya leads strategy at PharmaForceIQ. With over 15 years of pharma marketing experience from roles at Merck, AstraZeneca, IQVIA, and other firms, Hemal leads multiple business functions and advises clients on strategy.

Winnie Pun is published by Sectoral Asset Management as Director Hong Kong. Hong Kong director with earlier BlackRock institutional-business and public-policy leadership. Her2023 retirement and former association appointments are historical background.

Jivka Angelova is published by Sectoral Asset Management as Head of Operations. Leads investment-product operations and supports IT oversight, with a McGill-HEC executive MBA and accounting education. The biography identifies joining inMay2026; exact day undisclosed.

James Xie is published by Sectoral Asset Management as Compliance Manager. Works on compliance policies, registration, filings, regulatory risk and monitoring, with management and graduate business education.

Thierry Martin is published by Sectoral Asset Management as Senior Advisor- GCC. Supports Gulf-region coverage as a senior advisor after a banking career at UBS and NBK Banque Privée. Earlier military and banking history is source-published background.

Kevin Vos is published by Sectoral Asset Management as Associate. Biotechnology venture associate with a Victoria physical-chemistry PhD and earlier Bold Therapeutics pipeline and business-development work.

Thierry Abribat is published by Sectoral Asset Management as Industry Partner (published affiliation). Biotechnology entrepreneur whose background includes Alizé Pharma and Amolyt Pharma exits; published industry affiliation is separate from a current employee role.

Adil Essakhi is published by Sectoral Asset Management as Systems Administrator. Works on systems infrastructure, network operations and cybersecurity, with earlier payments-technology and transaction-processing experience.

Christopher Kent is published by Sectoral Asset Management as Principal. Medical-technology investor with a McGill neuroscience PhD and entrepreneurial experience developing Reveal Surgical’s AI-enabled optical system for molecular guidance during tumor surgery. Current Principal card supersedes the biography’s earlier Senior Associate joining title.

Philippe Demers is published by Sectoral Asset Management as Industry Partner (published affiliation). Cardiothoracic surgeon and academic with aortic, valve-repair and endovascular experience in Montreal.

Uday Kumar is published by Sectoral Asset Management as Industry Partner (published affiliation). Physician and wearable medical-device entrepreneur associated with Element Science and iRhythm; industry affiliation is distinct from an investing staff position.

Nizar Zein is published by Sectoral Asset Management as Industry Partner (published affiliation). Hepatology physician and researcher with Cleveland Clinic leadership experience. Source-published clinical background does not imply employment by Sectoral.

Arek Alszko is published by Sectoral Asset Management as Director of Information Technology. Leads information-technology operations, infrastructure, security and systems support for the manager.

Toby Ma is published by Sectoral Asset Management as Financial Analyst. Covers medical devices, diagnostics and life-sciences tools; holds a Memorial University medicine PhD.

Wayne Mah is published by Sectoral Asset Management as Portfolio Manager. Manages the biotechnology strategy after a2024 portfolio-manager promotion; holds an HEC Montréal MBA and McGill chemistry master’s degree.

William N. Starling is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Life-sciences entrepreneur and venture investor associated with Synergy Life Science Partners and Synecor; this published advisory relationship is not a newly identified individual cash ticket.

Vannesa Wong is published by Sectoral Asset Management as Business Development Manager. Works on Hong Kong client relationships, marketing and office operations, with earlier banking experience.

Gauthier Sanz is published by Sectoral Asset Management as Senior Analyst. Supports portfolio reporting, reconciliation and client-service operations; holds corporate-finance graduate education.

Catherine Protopoulos is published by Sectoral Asset Management as Senior Accountant. Supports fund and manager reporting, audit and tax work, with earlier investment-industry treasury experience.

David Veino is published by Sectoral Asset Management as Industry Partner (published affiliation). Medical-device commercial executive identified by the manager as Neuros Medical CEO, with earlier cardiovascular and surgical-device roles. Sectoral affiliation is Industry Partner, distinct from investing staff.

Jeanne Magram is published by Sectoral Asset Management as Industry Partner (published affiliation). Drug-discovery executive whose published experience includes scientific leadership at Montage Bio and Celsius Therapeutics, including single-cell precision-medicine work.

Gabriel Douville is published by Sectoral Asset Management as Principal. Supports Fonds Medtech Ventures research and diligence on early-stage medical technologies; published board-observer affiliations do not imply personal investment tickets.

Frederic Pfund is published by Sectoral Asset Management as Former Marketing Assistant (In memoriam). The official biography and original portrait explicitly mark In Memoriam. He formerly supported public relations, business development and office activities while studying economics at Concordia; no current employee or invented death date is asserted.

Michael Sjöström is published by Sectoral Asset Management as Co-founder & Partner. Co-founded Sectoral in2000 after pharmaceutical research and biotechnology portfolio management at Pictet. Holds a St.Gallen MBA and CFA charter; the manager identifies Route92Medical board-observer affiliation, distinct from a director or personal investor ticket.

Marco Cianflone is published by Sectoral Asset Management as Head of Public Equities & Senior Portfolio Manager. Oversees public-equity strategy, allocation and the investment team; studied economics at Harvard and holds the CFA charter.

Brett Goodin is published by Sectoral Asset Management as Director Australia. Investment-management executive whose background includes Fidelity International and later Bain advisory work; outside positions are separately qualified.

Vishar Subramanian Vasudevan is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Former Dr.Reddy’s financial executive and European subsidiary manager. The directory describes experience through2010, rather than current company employment.

Magdalena Leszczyniecka is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Biotechnology executive with STC Biologics and earlier Flagship and Atlas venture experience; outside titles remain source-published background.

Frank Ma is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Pharmaceutical entrepreneur associated with i-MD and FocusRx Research; published advisory affiliation does not identify a personal fund investment.

Amanda Adler is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Physician and epidemiologist with economics training and diabetes research experience. The manager publishes a scientific advisory background, not a current employee appointment.

Nury Cortez is published by Sectoral Asset Management as Office Administrator. Coordinates office operations and administrative support, with earlier nonprofit and mental-health organization experience.

Richard Sörberg is Head of Analytics at Ferrum Health, according to the company’s current October2026 Microsoft for Startups post. Its June29,2026 article identifies him as Head of Analytics and Insights. He works on evidence, performance measurement and clinical AI accountability. An authentic individually identified portrait was not available in the primary sources retrieved.

Mark Cai is published by Sectoral Asset Management as Financial Analyst. Covers biotechnology companies, including emerging markets; holds a Monash physiology PhD and earlier biochemistry and pharmacology education.

John Wilson is identified by Ferrum Health as Head of Marketing in its own Health Management Academy partnership announcement. His personal site, johnswilson.co, describes healthcare AI commercialization work at Ferrum and previous global enablement work for Google Cloud’s Healthcare AI portfolio. He advises on commercialization, positioning and financing; this does not establish an institutional investment check or a director appointment.

Yingdong Zhang is published by Sectoral Asset Management as Regional Director - Asia. Hong Kong-based investor-relations and business-development professional serving Asian investors, with earlier Nikko and UBS asset-management experience.

David Hilderbrand is Ferrum Health’s Chief Commercial Officer, leading commercial operations, revenue strategy and partnerships. His own company biography records previous leadership at Blackford, Rhapsody, Bayer Healthcare and Vital Images. The authentic company welcome graphic includes his named portrait.

Marc-André Marcotte is published by Sectoral Asset Management as Partner & Head of Venture Capital. Heads venture investments with a focus on medical devices, and participates in the management committee. Published portfolio board affiliations are distinct from personal cash tickets. Marc-André Marcotte is a current Iantrek board member and Sectoral Asset Management partner. The company card retains a COO description, while his manager’s current own directory identifies Partner and Head of Venture Capital; the manager’s current professional biography is preserved.

Austin Deer is VP of Sales at Ferrum Health, as identified in the company’s current October2026 post about its Microsoft for Startups partnership. He is listed in the current leadership directory. Older company publications describe him as Head of Strategic Partnerships; that older title is not substituted for the newer source.

John Regan is published by Sectoral Asset Management as Director of Finance. Oversees group accounting, audit and tax functions, with earlier finance leadership and Concordia accounting education.

J.R. Randall is Head of Strategic Alliances at Ferrum Health, according to the company’s current October2026 event announcement. He is listed in its public leadership directory and leads alliances including the AWS relationship. The current company confirms participation in the October6,2026 CHAI Fall Symposium; no specific appointment date is asserted.

Robert (Bobby) Higgins co-founded Masters Special Situations in 2020 and was identified as managing director and general counsel in Greenbrook’s August 2021 announcement. CongruityHR currently lists him as chief operating officer and general counsel, describing Masters Special Situations as previous experience. Exact MSS departure date and an authentic public portrait have not been verified.

Michel Aguet is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Physician and molecular-oncology researcher whose background includes Genentech and directing ISREC from1996 to2009. Outside academic titles may be historical.

Jamie Bergen is a member of Ferrum Health’s public leadership team. Its own February2026 publication identifies her as Director of Operations and Insights, leading work on clinical AI measurement, ground truth and observability. A June2026 conference organizer calls her Director of Customer Success; the exact latest title is not supplied by the current company directory.

Anthony (Ant) Raab is identified by the December 2021 Venus Concept issuer announcement as managing director of Masters Special Situations. Masters Capital Management currently lists him as a senior investment research analyst covering financial and healthcare companies. He joined that affiliate in 2015 after work at Perimeter Capital and TCW, and graduated from Duke University in economics.

François Beaubien is published by Sectoral Asset Management as Partner. NEMO biotechnology investor with a McGill neuroscience PhD, UBC MBA and CFA charter, working on deal flow and scientific diligence.

Peter Eason is Ferrum Health’s Chief Financial Officer, overseeing finance, accounting, capital strategy and operations. He has experience scaling venture-backed healthcare and enterprise software companies and previously held CFO roles. Current directory title is CFO; older publications also called him CFO/COO.

Michelle Dobbins was identified as a managing director of Masters Special Situations in its 2021 fund filing. Masters Capital Management currently lists her as partner and chief financial officer; she joined the affiliate in 1999. She previously founded Partnership Financial Consulting and worked at Northside Hospital and Arthur Andersen. She graduated from the University of Florida.

Jérôme Pfund is published by Sectoral Asset Management as CEO. Co-founded the Montreal manager with Michael Sjöström in2000 after Pictet investment-management roles. Holds a St.Gallen MBA and CFA charter; opened the Hong Kong office in2013.

Kenneth Ko, also published as Ken Ko, is co-founder and CTO of Ferrum Health. He leads engineering and the technical architecture of the company’s interoperable governance platform, including deployment, validation and monitoring of clinical AI within health-system-controlled environments. Before Ferrum he built distributed systems for healthcare and consumer platforms. Education omitted because the current company biography and earlier attributed biography disagree on institution.

Gregory (Greg) Pope was identified as a managing director of Masters Special Situations in its 2021 fund filing. Masters Capital Management currently lists him as partner, portfolio manager and chief operating officer; he joined that affiliate in 2000 after working at J.C. Bradford. He studied finance at Georgia State University.

Jonathan Ma is published by Sectoral Asset Management as Operations Analyst. Works on cash and positions reconciliation, portfolio accounting and reporting; studied finance at Concordia University.

Pelu Tran is co-founder and CEO of Ferrum Health, leading its enterprise clinical AI governance business. He previously co-founded clinical documentation company Augmedix and worked at the intersection of medicine and machine learning at Stanford. His current own company biography describes Stanford education without a verified completed medical degree; no MD qualification is asserted.

Antoine Blondin is published by Sectoral Asset Management as Regional Director – Europe. Supports European business development and marketing, with education in financial markets and accounting.

Vincent Duhamel is published by Sectoral Asset Management as Director Canada. Investment-management executive with earlier leadership at Fiera Capital and institutional asset management in Asia.

Director of Clinical Trial Services at CortiCare. Published in the current leadership directory for the company’s EEG-monitoring and interpretation services supporting neurological research.

Senior Director of Clinical Services at CortiCare. The current directory publishes her EEG, long-term-monitoring, intraoperative-monitoring, nerve-conduction and neurophysiologic credentials.

Associate Vice President of Information Technology at CortiCare. Holds an MBA and is identified in the company’s current leadership directory with an official named portrait.

Associate Vice President of Outpatient Services at CortiCare. Holds registered polysomnographic and EEG technologist credentials and an MBA in Healthcare Management, as published in the current directory.

Vice President of Operations for Ambulatory Services at CortiCare. Holds a bachelor’s degree and registered EEG technologist credential, as published in the current leadership directory.

Vice President of Operations for Physician Services and Editing at CortiCare. Published in the company’s current executive leadership directory with an official named portrait.

Vice President of Client Relations at CortiCare. Member of the current executive leadership directory for the company’s remote EEG-monitoring and interpretation services.

Vice President of Business Development at CortiCare. Listed in the company’s current executive directory, which identifies leaders serving hospitals, neurological practices and clinical-trial programs.

Vice President of Human Resources at CortiCare since joining in March2023. Holds SHRM-SCP and SPHR certifications and leads the company’s HR function, supporting employee development, recruitment and organizational growth.

Senior Vice President of Operations at CortiCare. Member of the company’s current executive leadership team supporting its nationwide EEG and neurodiagnostic services.

Chief Financial Officer at CortiCare, the remote EEG-monitoring and neurodiagnostic services company. Listed in its current executive leadership directory with a named official portrait.

Chief Executive Officer of CortiCare and a member of its board. Joined the company in 2023, bringing more than twenty-five years of healthcare executive experience across hospitals, health systems and physician services. Holds MBA and FABC credentials.

Justin Gélinas is published by Sectoral Asset Management as Senior Manager, Risk & Operations. Works on public-equity middle-office operations and risk, with Concordia finance education and CIPM and FRM qualifications.

Angus C. Russell is published by Sectoral Asset Management as Advisory Network member (published affiliation; current activity unverified). Former Shire chief executive who retired in April2013. The published advisory biography is background, not current Shire employment.

Howard Riback is published by Sectoral Asset Management as Director, Venture Capital. Provides financial diligence, legal review and transaction documentation support; earlier experience includes Ventures West and Chrysalix.

Works on partnerships supporting land restoration projects.

Leads operations for the land restoration business.

Leads commercial work for Bumi Baru’s land restoration and development business.

Leads degraded land development; previously CFO at Swap Energi and co-founder and CFO at Eden Farm.

Leads development of affordable solar products and household adoption models for Southeast Asia.

Product and management professional with agriculture, pharmaceutical and biotechnology experience.

Finance professional with experience in Indonesian fintech licensing, compliance and fundraising.

Works on strategy, business development and partnerships with a focus on environmental and social outcomes.

Executive with experience in banking, insurance, partnerships and financial risk management.

Agronomist with experience in agribusiness, sales and project management.

Business development professional with experience in renewable energy, financial technology and consumer products.

Entrepreneur with a prior exit and energy venture building experience at Roland Berger and Rainmaking.

Thai technology entrepreneur known as JoeZ, with a previous company exit in 2022.

Dan Lynn co-founded ZUZU Hospitality after leadership roles at Expedia and AirAsia Expedia. He subsequently joined Inspire Brands; his founder designation does not imply a current executive position at ZUZU.

Operations and finance leader of New Leaf Venture Partners. The current team card and profile heading identify COO and CFO; the biography also uses chief administrative officer. He oversees finance, operations, compliance and human resources, joined Sprout as CFO inAugust2002 and participated in its2005 healthcare spinoff. Previously in audit and assurance at Arthur Andersen and Ernst & Young, he holds degrees from Columbia Business School and Queens College and is a certified public accountant.

Co-founder and managing director of New Leaf Venture Partners, focused on information convergence and diagnostics. He joined Sprout in1998 and became a partner in2003 before co-founding NewLeaf in2005. Earlier work included healthcare venture investment and financial analysis; he studied chemical engineering at MIT and Stanford. Prior Sprout investments are distinct from later NewLeaf firm checks.

Co-founder and managing director of New Leaf Venture Partners, focused on early- through late-stage biopharmaceutical investments. A founder of the2005 firm, he previously worked in venture investing, pharmaceutical and device strategy and operations consulting, and sales and marketing at Johnson & Johnson and SmithKline Beecham. He holds a Wharton MBA and Cornell bachelor’s degree.

Mike Maher is a USVP senior advisor and former chief financial officer. He joined in1991 and served as CFO until July2016; the official team directory retains him as a senior advisor and the CFO transition biography describes a consulting role. Before USVP he was an Ernst&Young audit partner, with17 years at the firm. He has participated in investment valuation and industry accounting bodies and holds a Santa Clara bachelor’s degree.

Philip (Phil) M.Young is a USVP senior advisor who joined in1990 after investing at Concord Partners. Earlier he led critical-care instrumentation company Oximetrix through its acquisition by Abbott, worked at New Court Securities and McKinsey, and served in Admiral Rickover’s atomic-energy program. His investing experience includes medical devices, biotechnology and software. He holds Cornell mechanical-engineering, George Washington engineering-physics and Harvard MBA degrees. Older biography board lists are not independently treated as current appointments.

Steve Krausz is a USVP senior advisor with decades of enterprise software, semiconductor and communications investment experience. His published investment history includes Box, Guidewire, Imperva, CheckPoint, NewFocus and Sierra Monolithics. He has held leadership roles at the NVCA and Western Association of Venture Capital. He holds Stanford electrical-engineering and MBA degrees. The current directory identifies him as senior advisor; earlier general-partner references are historical or fund-specific.

Irwin Federman is a USVP senior advisor. He joined in1990 as a general partner after leading Monolithic Memories from1978 to1987 and becoming AMD vice chairman following its merger. His investment history includes semiconductor, communications and software companies such as SanDisk, Mellanox and Nuance. He is a former Semiconductor Industry Association chair and holds a Brooklyn College economics degree and honorary Santa Clara engineering doctorate. The current directory classifies him as senior advisor, rather than an active general partner.

Dale Holladay is USVP’s chief financial officer, responsible for financial reporting, tax, regulatory compliance and financing support. He joined in2001 as controller and later succeeded Mike Maher following a transition described in the official biography. The current directory confirms his CFO position; no exact appointment day is inferred from the older transition narrative.

Jacques Benkoski is a USVP general partner who joined in2005 and invests in US and Israeli enterprise software, cloud and security companies. He previously led Monterey Design Systems through its acquisition by Synopsys and established Epic Design Technology’s European business. Earlier he worked at IMEC, IBM and STMicroelectronics. He holds a Technion computer-engineering degree and Carnegie Mellon master’s and doctoral degrees, has published technical research, and authored The Market Entry Strategy.

Dafina Toncheva is a USVP general partner focused on enterprise SaaS and cybersecurity. She joined in2012 after investing at Tugboat Ventures and Venrock, where she led Cloudflare’s first institutional round. Earlier she worked on authentication, digital signatures and workflow at Microsoft and coauthored patents. Her published USVP investments include Arkose Labs, Carrot Fertility, Luma Health, Percepto and Surgical Safety Technologies. She holds a Stanford MBA and a Harvard computer-science degree.

Claire Jen is deputy general counsel at Coatue (2022–present) and secretary of the Coatue Innovative Strategies Fund, confirmed in its July2026 SAI supplement. She was formerly assistant general counsel at Rent the Runway (2018–2022).

Heather Shaffer is senior regulatory counsel at Coatue (2026–present) and became chief compliance officer of its CTEK fund on June29,2026. She previously worked as a staff attorney in the SEC Division of Enforcement (2019–2026). Fund CCO is distinct from the manager’s CCO Evan Rosenberg.

Ben Schwerin joined Coatue as a general partner in2023 focused on consumer and internet investing. His own2026 announcement describes joining portfolio company Instinct, so continuing current Coatue employment is not assumed.

Dan Rose identifies himself as a senior advisor at Coatue on his own public profile. He formerly held leadership roles at Amazon and Facebook and has served as chairman of Coatue Ventures. This is the technology investor, distinct from the medical device executive Dan Rose.

Matt Watkins was appointed Coatue chief regulatory counsel in July2024 and announced as chief compliance officer effective January2025. July2026 SEC ADV identifies Evan Rosenberg as current CCO; Watkins is retained as a historical role, with exact end date unavailable. Previously he held compliance roles at KKR, Morgan Stanley and the SEC.

Frank Long coauthored Coatue's July7,2026 research on AI agents and CPUs. A specific investment rank and fuller individual biography are not published in the reviewed firm sources.

Evan Rosenberg is Chief Compliance Officer & Chief Regulatory Counsel at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Brent Duddie is General Counsel at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Eric Sacks is Chief Financial Officer & Co-Chief Operating Officer at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Joanna Albright is Co-Chief Operating Officer at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Nathan Urquhart is President & Head of Strategy at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Philippe Laffont is Founder & Portfolio Manager at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Jaimin Rangwalla is Chief Investment Officer, Public Equities at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Michael Barton is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 01.07.2026. A current individual rank and full biography are not published in the reviewed sources.

Jason Kahn is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 01.20.2026. A current individual rank and full biography are not published in the reviewed sources.

Nick Gagnet is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 07.07.2026. A current individual rank and full biography are not published in the reviewed sources.

Max Cook is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 07.29.2026. A current individual rank and full biography are not published in the reviewed sources.

Vibhor Khanna is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 04.22.2025. A current individual rank and full biography are not published in the reviewed sources.

Armin Kohan is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 02.26.2025. A current individual rank and full biography are not published in the reviewed sources.

Sri Viswanath was publicly named in Coatue's 2025 investment commentary. He subsequently founded enterprise AI company Sycamore; the September3,2026 Smart AI Summit names him CEO of Sycamore and former Managing Director of Coatue. His current Coatue employment is not asserted.

Spencer Peterson is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 03.26.2025. A current individual rank and full biography are not published in the reviewed sources.

Rohan Bharvani is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 10.28.2025. A current individual rank and full biography are not published in the reviewed sources.

Brendan O’Boyle is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 11.24.2025. A current individual rank and full biography are not published in the reviewed sources.

David Schneider is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 01.28.2026. A current individual rank and full biography are not published in the reviewed sources.

Pranav Anand is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 05.28.2026. A current individual rank and full biography are not published in the reviewed sources.

Caryn Marooney is a general partner at Coatue sinceNovember2019, confirmed by its own2025 ClickHouse investment announcement and the2025 Elastic proxy statement. She serves as a ClickHouse board observer and Elastic director. She formerly led global communications at Meta and co-founded/led the OutCast Agency. She holds a BS in Labor Relations from Cornell University.

Philena Sun is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 07.20.2026. A current individual rank and full biography are not published in the reviewed sources.

Jade Lai joined Coatue as a partner in2023 to invest in enterprise software, AI/ML, open source and data infrastructure, developer tools and security, according to her own public announcement. The firm names her in its July2026 Databricks and May2026 Anthropic investment commentary.

Abhi Srinivas is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 09.28.2026. A current individual rank and full biography are not published in the reviewed sources.

Lucas Swisher is publicly named as a Coatue investment or research contributor in the firm's own investment commentary. Latest reviewed dated byline: 03.30.2026. A current individual rank and full biography are not published in the reviewed sources.

Thomas Laffont is Co-Founder & Chief Investment Officer, Privates at Coatue Management, L.L.C., confirmed in its July29,2026 SEC Form ADV Schedule A.

Former Breakthrough Victoria board director. Its 2025 audited board attendance report records appointment 1 October 2022 and cessation 4 July 2024. No undisclosed credentials or current standalone-manager role are inferred.

Executive director for strategic initiatives at Breakthrough Victoria until 10 January 2025, on secondment from Victoria’s Department of Jobs,Skills,Industryand Regions, as explicitly stated in the 2025 annual report.

Breakthrough Victoria CEO from November 2021 until 29 November 2024, according to its audited 2025 report. Previously held leadership roles at ARAInfrastructure and Hastings Funds Management. His successor was acting CEO Lauren Morrey and then Rod Bristow.

Led Breakthrough Victoria portfolio asset management until 13 June 2025. Previously founding partner and first CEO of Bridges Australia, with finance and investment roles at Accenture, JPMorgan and SBCWarburg. Holds Monash economics and accounting qualifications and received an Order of Australia award for ethical-investment work.

Led later-stage investment sourcing at Breakthrough Victoria. His 2025 report biography describes funds management, mergers and acquisitions, sustainability, civil engineering, investment-bank experience in Australia and the United States and a corporate-finance advisory business. Holds engineering qualifications from Monash University and a Melbourne Business School finance MBA.

Legal and governance executive who served as Breakthrough Victoria’s general counsel and company secretary. Her 2025 report biography describes prior private-sector professional-services, engineering and agricultural experience. Monash University law graduate and Governance Institute fellow.

Led Breakthrough Victoria’s corporate operations across finance, risk, compliance, information technology and people functions. Previously worked in innovation at National Australia Bank and ANZ. Holds a Melbourne Business School MBA and applied social-science degree. Also served as acting CEO from 29 November 2024 to 10 February 2025.

Interventional cardiologist, professor and former Boston Scientific executive vice president and global chief medical officer, retired from that executive position in 2023. His 2025 Breakthrough Victoria biography describes clinical trials, medical-device development and leadership participation in Boston Scientific’s internal venture investment program. Served on Breakthrough Victoria’s board.

Tristan Zier is Chief of Staff at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Kale Yeung is Deputy CCO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Reggie Williams is Senior Director, Head of Early Talent at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Andreas Weiland is Principal Designer at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Jane Wei is Head of Strategic Operations at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Hem Wadhar is VP of Data Science at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Brenda Tran is VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Caleb Tennis is CISO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Ian Taylor is Senior Director, Ecosystem and Platform Analytics at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Anna Swank is Senior VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Jung Son is CLO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Valerie Sarnataro is Senior Director, Communications at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Avon Puri is CDO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Hoangdan Nguyen is VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Alex Moore is Senior Director, Content at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Natalie Miyake is Partner, Marketing at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Emma Matthieson is Senior Director, Marketing Experiences at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Patricia Ma is Senior Director, People Ops at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Theresa Lee is Partner and Head of Talent at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Jess Lee is Partner And CPO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Oh Sung Kwon is Associate General Counsel at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Jacquie Kush is VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Marie Klemchuk is CFO at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Cindy Kim is VP of Finance at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Ankur Jain is VP of Applications and Data at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Mary Glide is VP of Technology at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Stacey Gerber is Partner, Marketing and Operations at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Kathleen Forte is Partner, Investor Relations at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

James Buckhouse is Partner, Design at Sequoia Capital, according to its current published operating-team directory. The role supports the firm’s venture investing and portfolio operations. No additional personal background or employment dates have been inferred.

Sonali Singh is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Andrew Reed is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Abhishek Malani is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Dev Ittycheria is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Sonya Huang is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Brian Halligan is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Ravi Gupta is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Pat Grady is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

James Flynn is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Carl Eschenbach is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

David Cahn is listed on Sequoia Capital’s current growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Stephanie Zhan is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

George Robson is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Lauren Reeder is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Dean Meyer is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Shaun Maguire is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Pat Mackin is Director at Route 92 Medical. Also known as J. Patrick Mackin, the Chairman, President and CEO of Artivion. Medical-device executive with previous Medtronic cardiac rhythm and vascular leadership, Genzyme experience and US Army service.

Lucas Buchanan is Director at Route 92 Medical. Medical-device finance and operations leader who previously served as Silk Road Medical CFO and COO through its 2024 acquisition by Boston Scientific. His background includes The Vertical Group, Impax and Medtronic.

Luciana Lixandru is listed on Sequoia Capital’s current seed and early-stage and growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Mitch Hill is Director at Route 92 Medical. Healthcare finance and operations executive and former Inari Medical CFO. His earlier career included several medical-device and other public-company CFO positions; studied at Brigham Young and Harvard.

Alfred Lin is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Noel Jee is Director at Route 92 Medical. Life sciences investor and Novo Holdings partner with earlier experience at Sofinnova, Illumina Ventures and L.E.K. Holds a UCSF doctorate in chemistry and chemical biology. Current primary team specifies Venture Investments; historical appointment release said Growth Investments. Noel Jee is a Partner in the Venture Investments team at Novo Holdings based in San Francisco. Noel contributes a balance of investment acumen for evaluating life science investment opportunities, strategic advisory, and operational support skills for portfolio companies. Previously an investor with Sofinnova Investments and Illumina Ventures, Noel honed his investment experience across therapeutics, life science tools, diagnostics, and healthcare platforms. Noel’s time at Illumina Ventures also included 10 months operating a portfolio company. Prior to his time in venture capital, he was a management consultant at L.E.K. Consulting where he advised large and small-cap biopharma and diagnostics companies on a variety of strategic projects, from asset M&A to pipeline prioritization and expansion. Noel received his PhD in Chemistry and Chemical Biology from the University of California, San Francisco. Noel also holds a B.S. in Biochemistry and a B.S. in Neurobiology and Physiology from the University of Maryland, College Park.

Doug Leone is listed on Sequoia Capital’s current seed and early-stage and growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Jim Goetz is listed on Sequoia Capital’s current seed and early-stage and growth investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Operating-team member affiliated with 1315 Capital since 2023, expressly identified as a nonemployee. Leads North American generics at McKesson and previously worked as a Managing Director at Healthcare Value Capital. Also known as Robert Schrepfer.

Operating-team member affiliated with 1315 Capital, expressly identified as a nonemployee. Co-founded Bonafide Health and previously served as its CEO, led Nutrition21, and co-founded JDS Pharmaceuticals, whose products addressed psychiatric and women’s health conditions.

Operating-team member affiliated with 1315 Capital, expressly identified as a nonemployee. Has more than three decades of leadership experience in medical devices, diagnostics and consumer products, including service as CEO of DNA Diagnostics Center.

Operating-team member affiliated with 1315 Capital, expressly identified as a nonemployee. Has executive experience across healthcare diagnostics, laboratories, pharmaceutical services and contract manufacturing, including business integrations and turnarounds.

Associate at 1315 Capital since joining in 2025. Previously worked in healthcare-services investment banking at Raymond James and interned at Stone Pier Capital. Studied finance at the University of Pittsburgh.

Director of Business Development at 1315 Capital since joining in 2020. Previously served as an Investment Associate at ProMedica, supporting debt and equity financing and ProMedica Ventures’ investment portfolio.

Associate at 1315 Capital since joining in 2024. Previously worked at Health Advances on medical technology, digital health and healthcare information technology. Earlier internships included Vayu and BioVentures Investors; studied at Dartmouth.

Associate at 1315 Capital, joining in 2026. Previously worked in healthcare investment banking at Morgan Stanley and interned at Prudential Private Capital. Studied at Emory University’s Goizueta Business School.

Principal at 1315 Capital since joining in 2016. Previously worked in investment banking at Leerink Partners and undertook a business-development secondment at JDS Therapeutics. Supports healthcare investment evaluation and portfolio-company development.

Principal at 1315 Capital since joining in 2015. Previously worked as a healthcare management consultant at Capgemini and in quality engineering at Stryker. Serves on boards including CortiCare, 3B Scientific and miraDry.

Vice President at 1315 Capital since joining in 2020. Previously worked at MTS Health Partners and in corporate strategy and business development at Pacira. Serves on CortiCare’s board and observes several healthcare portfolio-company boards.

Office Manager at 1315 Capital, as listed in the firm’s current team directory. The firm publishes a named portrait and role but no separate professional biography.

Principal at 1315 Capital since joining in 2020. Previously invested in healthcare technology, medical technology and services at Northwell Ventures. Earlier experience includes biopharmaceutical business development and healthcare investment banking at Piper Jaffray.

Analyst at 1315 Capital, joining in 2026. Previously worked in healthcare investment banking at Goldman Sachs and completed an investment-banking internship at HSBC. Holds a degree from Duke University.

Business Development Associate at 1315 Capital since joining in 2025. Previously worked in sales and marketing analysis at Rescription and interned in institutional equities at Canaccord Genuity. Studied history at Trinity College.

Controller at 1315 Capital since joining in 2018. A CPA, she previously audited financial-services clients at KPMG. Holds an accounting degree from Temple University and supports the firm’s financial reporting and fund operations.

Senior Accountant at 1315 Capital, joining in 2026. Supports fund accounting, reporting and treasury. Previously worked at SEI and Citco and on consulting assignments for JPMorgan; studied accounting at Neumann University.

Chief Financial Officer and Chief Compliance Officer at 1315 Capital since 2014. Oversees fund accounting, treasury, investor reporting, risk and regulatory compliance. Previously worked with Adele Oliva as Quaker Partners’ CFO.

Partner at 1315 Capital since joining in 2017. Previously spent nine years at HealthCare Royalty Partners, where he was a Managing Director. Invests across healthcare products and outsourced services and serves on portfolio-company boards.

Co-founded 1315 Capital in 2014. Previously led healthcare investing as a Managing Director at Palm Ventures, following a decade at Galen Partners. His experience spans investment management and healthcare operating-company boards.

Co-founded 1315 Capital in 2014, investing in commercial-stage healthcare businesses. Previously joined Quaker Partners in 2007 and served as co-head of US Healthcare at Apax Partners. Serves on several healthcare portfolio-company boards.

Jonathan Root is Director at Route 92 Medical. Physician and USVP general partner, also known as Jon Root. His background includes neurology faculty and clinical leadership at Cornell; his USVP biography independently confirms the Route 92 board appointment. Current own USVP biography: Jonathan (Jon) Root is a USVP general partner and neurologist. He joined in1995 as a Kauffman Fellow and became a general partner in1997. Before investing he was an assistant professor of neurology and directed the neurology-neurosurgery special-care unit at New York Hospital–Cornell. His current own USVP biography identifies board service at Route92Medical, Nervonik, Carlsmed and other healthcare companies. His Inari board service ended with its February2025 acquisition. He holds Dartmouth economics, University of Florida medical and Columbia MBA degrees.

Liam Corrigan is listed on Sequoia Capital’s current seed and early-stage investment team. The firm’s individual published profile describes this investor’s background and portfolio. This current firm affiliation is verified from Sequoia’s own directory; no inferred start date or unconfirmed partner seniority is assigned.

Jack W. Lasersohn is Director at Route 92 Medical. Healthcare venture investor and general partner of The Vertical Group, with earlier legal work at Cravath. Trained in physics and law. The Vertical Group publishes Jack W. Lasersohn as a general partner. He entered the venture-capital operation of predecessor F. Eberstadt in 1981 after legal work at Cravath, Swaine & Moore. His education includes physics at Tufts, international affairs at the Fletcher School and law at Yale. He has served in NVCA leadership and on federal medical-device advisory initiatives.

Renée Kochevar is Vice President, Clinical Research at Route 92 Medical. Clinical research executive with experience designing and delivering worldwide device, diagnostic and combination-product clinical programs, including early and later development stages.

Bob O’Brien is Vice President, Strategic Alliances at Route 92 Medical. Neurovascular commercial and account-management professional with earlier roles at MicroVention, Medtronic Neurovascular and Bard Peripheral Vascular.

Randall Sullivan is Senior Vice President, Operations at Route 92 Medical. Medical-device operations executive with former senior roles at Imperative Care, Silk Road Medical and MicroVention, plus manufacturing and operations experience in other device companies.

Founder, CEO and managing director of Household Capital and former GBSVentures partner. Served on Breakthrough Victoria’s board with experience in biotechnology investment and company boards including Celladon, Peplin and Spinifex. Rhodes Scholar with an Oxford doctorate in intellectual property for biotechnology.

Cindy Lynch is Senior Vice President, Legal Affairs at Route 92 Medical. Medical-device legal and intellectual property professional with earlier in-house roles at Conor Medsystems, Moximed, Simplify Medical and Elixir Medical. Former USPTO patent examiner and registered patent attorney.

Board director and finance, operations and risk executive with experience in health, insurance and the public and nonprofit sectors. The 2025 report names her as a Breakthrough Victoria director and risk/audit committee chair. She holds management-science qualifications and professional accounting and company-director fellowships.

John Miller is Chief Technology Officer at Route 92 Medical. Medical-device engineering and research executive with prior R&D leadership at Roxwood Medical and Concentric Medical, including ischemic-stroke device development.

Provides operations and administrative support and volunteers with Greenpeace.

Supports partners with scheduling, travel and stakeholder administration.

Finance professional with experience in payments and international currency operations.

Leads finance and operations; former Ikhlas Capital CFO with private equity and investment banking experience.

Previously helped build Uravu Labs and supported startup investment and fundraising.

Previously advised India’s Ministry of Agriculture on marketing and supported agricultural startups.

Has experience in product management and early stage investing, including GCash.

Chemical engineer with consulting and energy experience.

Supports portfolio companies from creation through expansion.

Studies climate risk and the economics of methane reduction, with research experience at Columbia and Yale-NUS.

Works on sustainability ventures with experience in Vietnam expansion and environmental research.

Bioenergy engineer with strategy experience at Pitik and Mercer.

Previously supported companies and accelerators in Singapore’s public service.

BitGiving founder and former Meta partnerships executive.

Builds industrial and sustainability ventures; previously worked with EDB and the World Economic Forum.

Previously led product and growth work at Carro and Snapask.

Leads recruitment of founders for new climate companies.

Leads Indonesia venture building; previously worked at Uber, OYO and Gojek and co-founded plastics-related ventures.

Builds ventures with experience in consulting, digital platforms and strategy.

Environmental engineer and entrepreneur who built Flexicar and DC Power Co. Clean-economy entrepreneur and director with environmental-engineering training from the University of Melbourne. The 2025 report describes board and leadership experience across sustainable mobility, clean technology, environmental regulation and infrastructure, including Hysata, JETCharge, Energy Safe Victoria and Melbourne Water.

Leads India ventures after investing in agricultural and climate startups at Omnivore.

Technology executive and venture investor who served on Breakthrough Victoria’s board. Previously CEO of Sky Pilot Networks and associate partner at Mobius Venture Capital; earlier worked at Preview Systems and Apple. His 2025 biography also describes work with Skalata Ventures and the University of Melbourne accelerator. Notre Dame graduate.

Raj Denhoy is Chief Financial Officer at Route 92 Medical. Medical technology finance executive who previously served as CFO of Establishment Labs and worked in equity research at Jefferies, J.P. Morgan and Piper Sandler.

Chris Hartman is Chief Commercial Officer at Route 92 Medical. Medical-device commercial executive with former leadership in LivaNova’s epilepsy neuromodulation business and Stryker Neurovascular. His background also includes Option Care, Baxter and Boston Scientific/Guidant.

Led Breakthrough Victoria from 10 February 2025 and was appointed CEO of successor Innovation Victoria in 2026. His investment and operating career includes CEO roles at Investible, Clime Investment Management, Infocus Wealth Management and Greening Australia, and leadership at Comm Sec. He studied forestry at the Australian National University with postgraduate studies at AGSM and INSEAD.

Warren Kim is Consulting Medical Director at Route 92 Medical. Neurointerventional surgeon at Sutter Health California Pacific and Mills-Peninsula, with neuroscience research at Yale and clinical neuroradiology training at UCSF. His company position is consulting, distinct from employment.

Joey English is Chief Medical Officer and Co-Founder at Route 92 Medical. Neurointerventional physician who also leads services at California Pacific Medical Center and Mills-Peninsula. Previously worked in neurointerventional services at UCSF-affiliated hospitals.

Former premier of Victoria from 2007 to 2010 and treasurer from 2000 to 2007. Chaired Breakthrough Victoria’s board. The 2025 report describes his biotechnology, education and not-for-profit board experience, including Bio Curate and La Trobe University. The Victorian Government announced his departure during the 2026 Innovation Victoria transition.

Co-founder of Nascent, as stated in his published BoxOne Ventures professional biography. Also a BoxOne co-founder, he previously co-founded proprietary trading firm Vigilant Global, which DRW acquired in2012, and became a DRW partner. His background includes technology-driven financial markets and a genetics degree from Western University. He is absent from the current five-person Nascent public team page; this founder attribution does not establish a current venture partner title, full appointment date or independently verified portrait.

Investor and operator with previous strategy and corporate roles at BCG, Iformation Group, Michelin and Diageo.

Engineer and entrepreneur with experience building companies in Southeast Asia.

nuTonomy co-founder and clean technology investor; co-founded Wavemaker Impact.

PropertyGuru co-founder and climate investor; co-founded Wavemaker Impact.

Previously built ENGIE’s Southeast Asian venture studio across energy and industrial sectors; co-founded Wavemaker Impact.

Builds climate ventures in Southeast Asia and India; co-founded Wavemaker Impact.

Zoe Perret is publicly listed by Initialized Capital as Partner. Invests across seed stage sectors, including AI, energy and frontier technology, and supports follow-on fundraising.

Vivian Chaves is publicly listed by Initialized Capital as Head of Community. Runs founder community programs, events, resources and partnerships.

Tiffany Foo is publicly listed by Initialized Capital as Head of Talent. Helps portfolio founders recruit teams and develop company culture.

Robert Lindsey is publicly listed by Initialized Capital as Head of Finance Operations. Oversees fund operations and investor financial reporting.

Mitesh Singh is publicly listed by Initialized Capital as AI Engineer. Develops AI tools supporting the firm, with experience in software and data across several industries.

Marinda Luk is publicly listed by Initialized Capital as Chief Financial Officer. Leads finance, reporting, tax, audit, HR and financial planning.

Maeve Kelly Bodden is publicly listed by Initialized Capital as Administrative Assistant. Manages administrative support and the New York office.

Kim-Mai Cutler is publicly listed by Initialized Capital as Partner. Invests in technology connected to the physical world, including energy, property technology, AI and defense.

Esaul Delgadillo is publicly listed by Initialized Capital as Fund Controller. Supports fund operations and financial reporting after auditing asset managers at EY.

Cyndi Reseburg is publicly listed by Initialized Capital as Head of Communications. Leads communications, with prior experience at GV and technology communications agencies.

Chi An is publicly listed by Initialized Capital as Controller. Handles management company accounting and supports fund accounting.

Brett Gibson is publicly listed by Initialized Capital as Managing Partner. Invests in crypto, developer tools, AI and cloud infrastructure; previously founded software businesses.

Breanna Ross is publicly listed by Initialized Capital as Administrative Assistant. Supports San Francisco office operations and administrative work.

Becca Graff is publicly listed by Initialized Capital as Chief of Staff. Supports firm leadership and administrative coordination in the San Francisco office.

Abdul Ly is publicly listed by Initialized Capital as Partner. Invests in finance, enterprise software and application AI, following roles at First Round and Index.

Teh Bin Tean is an expert in medical genetics, epigenetics, Asian-prevalent cancers and drug discovery; Auristone lists him as Deputy Chief Executive Officer for Research at the National Cancer Centre Singapore.

Patrick Tan is an epigenomics and cancer biology researcher whose work includes molecular subtypes of gastric cancer and subgroup-specific treatments.

Chew Jing Ming is a biomedical engineer and medtech operator, previously Chief Operating Officer of a Series B gastric cancer medtech startup and a Singapore Stanford Biodesign Global Fellow.

Willson Cuaca is listed among Aevice Health’s board and management leaders and is Co-Founder and Managing Partner of East Ventures.

Nirdesh Gupta is listed among Aevice Health’s board and management leaders and serves as Managing Director of Coronet Ventures. Coronet Ventures’ current own directory additionally lists him as Chief Executive Officer and, on its Netherlands page, Managing Partner. Coronet is the international investment initiative of Cedars-Sinai Intellectual Property Company. His existing Aevice Health and Engine Biosciences board affiliations remain preserved.

Adrian Ang founded Aevice Health after his experience growing up with asthma motivated him to improve chronic respiratory disease management.

Venture partner at Nascent. Previously helped launch YAM Finance, consulted on smart-contract engineering and developed Ethereum trading and liquidation systems. His published background includes machine learning, engineering and finance. The current own title supersedes older third-party references to lead architect.

Published as Jessy, a venture partner on Nascent’s own team page. The firm supplies an illustrated avatar rather than a photographic headshot. A surname and separate professional biography are not established by the primary team card, so similarly named people are not merged and unrelated external positions or personal investments are not inferred.

Venture partner at Nascent. The firm’s biography describes earlier venture investment work at Polychain Capital and prior work at Victory Capital. His identity is corroborated by the exact full name in the primary portrait asset filename.

Leads People, Performance and Culture at Nascent. Her published biography describes leadership positions at the Rockefeller Foundation, Rippleworks and Living Goods, with work focused on human motivation, organizational performance and startup advising.

Co-founder of Nascent. Previously co-founded IDEO CoLab Ventures and helped launch YAM Finance, following work in social enterprise and microfinance. He earned an MIT Sloan MBA and a psychology degree from Pomona College and co-founded the MIT Bitcoin and FinTech clubs.

Tyler Brous manages LCP Quantum Management, LLC and LCP Quantum Management III, LLC, the managers of six LCP Quantum Partners investment vehicles identified in Infleqtion SEC filings. His current BBK Capital biography identifies him as a BBK partner and chief investment officer of Lennox Capital Partners, overseeing public and private investments. He has experience investing across public and private equity strategies and holds a BBA in Finance from the Canfield Business Honors Program at the University of Texas at Austin. BBK’s biography also lists board service, but current Infleqtion issuer disclosures identify his Infleqtion board service as former; this profile does not imply a current Infleqtion directorship or personal cash investment.

Colleen Clair is the Executive Assistant at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Melissa Childers is the Operations Specialist at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Lena Giacomini is the Chief Financial Officer at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Brad Feld is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Ryan McIntyre is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Chris Moody is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Jaclyn Hester is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Michael Nasser is a director and controlling individual of Satstreet Ventures Inc. Corporations Canada lists his full significant-controller name as Michael Joseph Henry Nasser. He is separately vice president, co-founder and chief compliance officer at Satstreet’s digital-asset brokerage. The brokerage biography describes earlier wealth/OTC leadership at Coinsquare and business development at Fidelity Investments.

Jonathan Lister, publicly known as Jon Lister, is a director and controlling individual of Satstreet Ventures Inc. He is separately president, co-founder and ultimate designated person at the Satstreet digital-asset brokerage. Its own biography reports earlier co-founding BlockEQ and wealth/OTC leadership at Coinsquare.

Seth Levine is a General Partner at Foundry, the Boulder-based venture capital firm historically known as Foundry Group. The firm’s current public team directory identifies this role.

Partner and Advisor at Kleiner Perkins. The firm's biography also identifies him as executive chairman and a founding partner of Ballistic Ventures. Ballistic Ventures affiliation: Ted Schlein is a co-founder and General Partner at Ballistic Ventures. His career includes venture investment and technology leadership across three decades at Kleiner Perkins and extensive cybersecurity company-building experience. His published profile describes advice to the US intelligence community and In-Q-Tel trustee service, with CISA committee service historical. His existing Kleiner Perkins affiliation, portrait, biography and personal financial graph are preserved.

Advisor to Kleiner Perkins chairman John Doerr, with a publicly documented 2016 joining year. Previously served as Deputy Chief Technology Officer of the United States and worked on federal digital-service initiatives.

Advisor listed in Kleiner Perkins' current public directory and former Vice President of the United States. His published biography identifies his climate advocacy and the founding of Generation Investment Management; dated external board memberships are not assumed current.

Advisor to Kleiner Perkins and a former partner at the firm. Her published investing work spans consumer technology, digital health and enterprise software; previously worked on product and operations at Uber.

Chairman of Kleiner Perkins and an engineer and venture investor. Authored books on organizational goals and climate action, including Measure What Matters and Speed and Scale. Cardigan’s own commissioned Neuro.VC branding case study identifies John Doerr as a founder alongside a neuroscientist. This institutional founder affiliation does not establish a separate personal cash investment or an unpublished daily operating/investment committee role.

Technical Talent specialist listed in Kleiner Perkins' current public team directory.

Experience Marketing specialist listed in Kleiner Perkins' current public team directory.

Business development specialist at Kleiner Perkins who joined in 2026. Develops partnerships connecting portfolio founders with large companies, including work on AI adoption and enterprise commercialization.

Go to Market Talent specialist listed in Kleiner Perkins' current public team directory.

Head of Marketing and Communications in Kleiner Perkins' current public specialist team.

Operating Partner for Business Development in Kleiner Perkins' current public specialist team.

Chief of staff at Lattice. Previously an analyst at Runa Digital Assets researching portfolios and managing operations for liquid token funds, following banking analyst experience in commercial and middle-market credit.

Chief operating officer of Lattice. Previously an early employee on Galaxy Digital’s asset management team and chief operating officer of healthcare-focused hedge fund Paqua Capital Management.

Partner and General Counsel in Kleiner Perkins' current public specialist team.

Co-founder and general partner of Lattice. Previously directed token listings at CoinList and worked at Meta on publisher monetization and marketing solutions, developing experience in digital networks and onchain capital formation.

Operating Partner for Marketing in Kleiner Perkins' current public specialist team.

Co-founder and general partner of Lattice. Previously co-founded Dove Metrics, later acquired by Messari, and worked at CoinList and AngelList. His experience includes token launches and go-to-market support for decentralized finance teams.

Chief Information Officer at Kleiner Perkins, with a publicly documented 2018 joining year. Oversees technology strategy, AI initiatives, cybersecurity, infrastructure and business intelligence.

Chief Financial Officer and Chief Operating Officer of Kleiner Perkins, as identified in its current public specialist directory.

Operating Partner for Engineering in Kleiner Perkins' current public specialist team.

Investor at Kleiner Perkins focused on growth companies, with a publicly documented 2026 joining year. Previously worked at TPG Capital and Morgan Stanley.

Kleiner Perkins principal who joined in 2023 and invests in AI, security and defense. Previously worked in technology investing at Thoma Bravo.

Principal in Kleiner Perkins' current public investment team. The firm identifies her as a coauthor of its April 2026 investment perspective on AI financial platform Rogo.

Partner at Kleiner Perkins, with a publicly documented May 2026 joining date. Works with founders building AI companies around specialist domain knowledge; an exact joining day is not published.

Partner at Kleiner Perkins focused on AI, enterprise applications, computing infrastructure and security. Previously worked in product management at Google.

Partner at Kleiner Perkins with early and growth investing experience. His published portfolio history includes Anthropic, Applied Intuition, Glean, Together AI and Waymo. Hakluyt Capital’s current advisory-board directory lists Mamoon Hamid as an external adviser and identifies his Kleiner Perkins investment experience. The affiliation is distinct from employment on Hakluyt’s investment team and does not establish a personal investment. Historical Social Capital co-founder: his current Kleiner Perkins biography confirms founding Social Capital in2011 and joining Kleiner Perkins in2017. The2013 FundII issuer FormD identifies him as director of its general partner’s general partner. This is a qualified historical affiliation, not current Social Capital employment or a personal cash investment.

Partner at Kleiner Perkins investing at early and growth stages. His public biography identifies board work with AI, enterprise and defense companies including Harvey, Rippling, Chai Discovery and Saronic.

Partner at Kleiner Perkins focused on companies applying AI to software and hardware. His published investment experience includes Browserbase, CuspAI, OpenEvidence, Synthesia and TerraFirma.

Partner at Kleiner Perkins investing in AI applications and computing infrastructure. Her published experience includes investments in Avoca, Poetic, Nooks, Applied Compute and Engram.

Aileen Stockburger is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Strategic-planning and corporate-transaction executive with almost30years at Johnson & Johnson, including medical-device business development and the Synthes acquisition. Her earlier accounting work was at PriceWaterhouseCoopers; she earned Wharton undergraduate and MBA degrees.

Guy de Panafieu is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Financial and industrial adviser whose career includes Crédit Agricole, Bull and Lyonnaise des Eaux, later ENGIE. He previously advised the French government on international economic relations.

François des Noyers is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Former manager of a Paris family holding company through2017, with multi-asset and healthcare private-equity experience. Earlier roles include Edmond de Rothschild holding companies, COFACE finance and Accenture consulting; he graduated from HEC Paris.

Patrick Miles is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Orthopedic technology executive with Alphatec Spine leadership and earlier NuVasive, Medtronic and Smith & Nephew experience. This is a published advisory affiliation with InnovaHealth, not an employee or individual investor ticket.

Thomas Kean is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Former New Jersey governor, Drew University president and chair of the9/11Commission, with healthcare and philanthropic governance experience. The directory’s outside organization titles are treated as source-published background.

Yves-André Istel is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Investment-banking veteran whose published background includes Hanseatic and Rothschild. Outside directorships mentioned in the manager biography may be historical and are not independently represented as current employment.

Lisa Granick is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Healthcare market and investment-diligence strategist with experience in cardiovascular, neurosurgical, orthopedic and women’s-health technologies. Earlier roles include Boston Consulting Group and Motorola.

Emme Deland is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Healthcare strategist with NewYork-Presbyterian, Mount Sinai and Brigham and Women’s experience. Her own foundation biography distinguishes the chief-strategy-officer position held beforeOctober2020 from later strategy-advisor work; obsolete outside titles on the manager directory are not treated as current appointments.

Tony Chou is published by InnovaHealth Partners as Strategic Advisor (published affiliation). Physician and medical-device entrepreneur with Route92Medical and The Vertical Group experience. The directory identifies an advisory affiliation, separate from investing staff or a personal cash ticket. Tony Chou is Founder and Chief Executive Officer at Route 92 Medical. Physician and medical-device entrepreneur with interventional cardiology training and former faculty and catheterization-laboratory leadership at UCSF. His operating background includes Abbott Vascular and investing at The Vertical Group. The Vertical Group publishes Tony M. Chou as a general partner. His medical-device operating background includes Abbott Vascular and cardiology at UCSF. He studied medicine at Case Western Reserve and physics and electrical engineering at Carnegie Mellon. Existing Route92 CEO and InnovaHealth advisory affiliations are preserved; these roles do not establish a personal investment check.

Natalia Stricker is published by InnovaHealth Partners as Executive Assistant. Manages New York office operations and coordinates research. Her earlier communications and public-affairs work involved international agriculture organizations in Paris; her education includes ISMaPP and Université de Nice Sophia-Antipolis.

Tiffany Cheynier is published by InnovaHealth Partners as Senior Manager - Investor Relations and Marketing. Communications and marketing professional responsible for investor relations and fundraising. Her background includes Lazard strategic planning and HealthpointCapital investor communications; she holds a Columbia master’s degree.

Noah Pereles is published by InnovaHealth Partners as Associate. Supports investment diligence, financial models, market research, portfolio monitoring and fundraising. Earlier corporate-development and M&A work at Sodali & Co followed consulting at Management Solutions; he earned an economics degree at Wharton. Current Associate title supersedes the old Senior Analyst browser title.

Ariella Golomb is published by InnovaHealth Partners as Senior Advisor. Physician and investment strategist with earlier HealthpointCapital and Boston Consulting Group experience. She holds a University of Pennsylvania MD and Wharton MBA; current own-directory title Senior Advisor supersedes the webpage’s old Managing Director browser title. Ariella Golomb is Director at Route 92 Medical.

Toby Cosgrove is published by InnovaHealth Partners as Senior Partner. Cardiothoracic surgeon and medical innovator who led Cleveland Clinic as President and CEO from2004 to2017. His clinical and healthcare leadership experience supports the manager’s medical-technology investments.

Kaspar Varmuza joined BOKA in 2023 and serves as chief of staff. His background includes strategic planning, UK government defense liaison and military operations. He formerly served as a major in the Grenadier Guards.

Lord Hugo Swire chairs BOKA’s investment committee. He previously represented East Devon in the UK Parliament and served as a minister at the Foreign and Commonwealth Office and Northern Ireland Office. His experience includes public and private company boards and international relations.